Can dialysis change how a kidney drug works? a trial investigates

NCT ID NCT07754331

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether hemodialysis—a treatment that filters waste from the blood when kidneys fail—changes how the body processes a combination drug called balcinrenone/dapagliflozin. The study will give a single dose of the drug to about 10 people with kidney failure who are on regular dialysis, then measure drug levels in the blood and dialysis fluid. The goal is to see if dialysis removes the drug and whether it is safe and well-tolerated in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
balcinrenone/dapagliflozin (a combination capsule of two drugs)
What this could lead to
If successful, this could help doctors understand how to dose this drug combination for people with kidney failure on dialysis, potentially improving treatment options for this population.
What could go wrong
This is a small, early-phase study focused on drug levels and safety, not on clinical outcomes. Results may not reflect real-world use, and the drug may still have side effects or fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.